Big Pharma executives have not been shy about their desire for deals, but companies have been battling macro headwinds ...

While cancelled NIH grants and regulatory uncertainty are less hospitable to clinical research in the U.S., Europe must play ...

NextCure is joining the China biopharma gold rush, partnering with Simcere Pharmaceutical Group on development of a novel ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

Sarepta’s shares crashed 41% in pre-market trading Monday morning to $21.01 after the biotech reported a second death from ...

Analysts at Truist Securities called J&J’s CAR-T readout “compelling,” noting that the efficacy figures could position the ...

At 12 weeks, weight loss ranged from 2.6% to 11.3%, compared to a gain of 0.2% in the placebo group. Guggenheim analysts were ...

Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...

At a satellite kickoff event to the annual BIO meeting, investment bankers and VCs gave reasons for optimism amid a ‘volatile ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

According to an internal email, the agency may be in for more consolidation in areas including human resources, ...

BIO International Convention (BIO2025), the world’s largest annual biotech event, will take place from June 16 to 19 (U.S.